| Completed | Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of NCT04953884 | Octapharma | Phase 3 |
| Unknown | Latin-American Von Willebrand Disease Registry NCT04279717 | Academia Nacional de Medicina | — |
| Unknown | Von Willebrand Disease in the Netherlands NCT03521583 | Erasmus Medical Center | — |
| Completed | rVWF IN PROPHYLAXIS NCT02973087 | Takeda | Phase 3 |
| Recruiting | A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebr NCT02932618 | Baxalta now part of Shire | Phase 3 |
| Completed | Molecular and Clinical Profile of Von Willebrand Disease in Spain NCT02869074 | Spanish Society of Thrombosis and Haemostasis | — |
| Completed | Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency NCT02792205 | Nantes University Hospital | — |
| Withdrawn | The Effect of the Nutraceutical "Hemofix" on the Coagulation System NCT01651468 | Hadassah Medical Organization | N/A |
| Completed | Registry of Patients With Von WilLEbrand Disease Treated With Voncento® NCT04657887 | CSL Behring | — |
| Completed | Study of Voncento® in Subjects With Von Willebrand Disease NCT02552576 | CSL Behring | Phase 4 |
| Completed | Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery NCT02283268 | Baxalta now part of Shire | Phase 3 |
| Completed | Willebrand International Non-interventional Global Surveillance NCT01949220 | Laboratoire français de Fractionnement et de Biotechnologies | — |
| Recruiting | Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patien NCT02472665 | Grifols Therapeutics LLC | Phase 4 |
| Completed | Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador NCT01589848 | Universidad del Azuay | — |
| Completed | Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease NCT01602419 | Octapharma | — |
| Completed | Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding NCT01410227 | Baxalta now part of Shire | Phase 3 |
| Completed | Extension Study of Biostate in Subjects With Von Willebrand Disease NCT01224808 | CSL Behring | Phase 3 |
| Completed | Study of Biostate® in Children With Von Willebrand Disease NCT01213446 | CSL Behring | Phase 3 |
| Unknown | Evaluation of Menses in Congenital Bleeding Disorders NCT01261936 | University of L'Aquila | — |
| Completed | Efficacy and Safety of IL-11 in DDAVP Unresponsive NCT00994929 | University of Pittsburgh | Phase 2 |
| Completed | Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease NCT00941616 | CSL Behring | Phase 2 / Phase 3 |
| Completed | Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII NCT00816660 | Baxalta now part of Shire | Phase 1 |
| Withdrawn | Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD) NCT00630448 | Weill Medical College of Cornell University | — |
| Withdrawn | A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willeb NCT00694785 | Archemix Corp. | Phase 2 |
| Completed | Acquired Von Willebrand Syndrome in Severe Aortic Stenosis NCT00805051 | University Hospital, Basel, Switzerland | — |
| Completed | A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced) NCT00701545 | CSL Behring | — |
| Terminated | IL-11 in Adults With Von Willebrand Disease Undergoing Surgery NCT00524225 | Margaret Ragni | Phase 2 |
| Completed | IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia NCT00524342 | Margaret Ragni | Phase 2 |
| Active Not Recruiting | Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients NCT00555555 | Grifols Biologicals, LLC | Phase 4 |
| Completed | National Study of Moderate and Severe Von Willebrand Disease in the Netherlands NCT00510042 | Erasmus Medical Center | — |
| Completed | The Von Willebrand Disease (VWD) International Prophylaxis Study NCT00557908 | Skane University Hospital | — |
| Terminated | Optivate in People With Von Willebrand Disease Undergoing Surgery NCT00404300 | Bio Products Laboratory | Phase 3 |
| Terminated | A Study With OPTIVATE® in People With Von Willebrand Disease NCT00387192 | Bio Products Laboratory | Phase 3 |
| Terminated | Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle NCT00178542 | The University of Texas Health Science Center, Houston | — |
| Completed | Phase II Study of IL-11 (Neumega) in Von Willebrand Disease NCT00151125 | University of Pittsburgh | Phase 2 |
| Completed | Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With NCT00168090 | CSL Behring | Phase 4 |
| Completed | A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemoph NCT02246881 | Bio Products Laboratory | Phase 3 |
| Completed | Treatment and Management of Women With Bleeding Disorders NCT00111215 | Centers for Disease Control and Prevention | N/A |